Abivax (ENXTPA:ABVX) Stock Sinks As Losses Deepen Despite Late Stage Progress

ABIVAX Société Anonyme entered this earnings report with a strong reputation for future growth and a share price that has been volatile but still relatively well supported, even as the stock declined 15.1% over the past month and 7.9% over the last week. The headline today is not the revenue line, which sits around €1.2 million for the quarter. The main story is the deepening loss, with Q2 net income showing a triple digit million euro deficit and basic earnings per share firmly in the red. For a high expectation biotech, that profit strain is what traders are reacting to.

Is ABIVAX Société Anonyme trading at a justified premium, or are traders paying too much for a loss-making biotech with a high P/B ratio and a price above the provided DCF estimate? See how the current share price compares with intrinsic value and peer benchmarks on our valuation analysis for ABIVAX Société Anonyme

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): €1.201 million vs. €1.047 million (higher quarterly revenue year on year)
• Net Loss, excl. extra items (Q2 2026 vs. Q2 2025): €117.433 million loss vs. €48.414 million loss (loss widened year on year)
• Basic EPS (Q2 2026 vs. Q2 2025): loss of €1.4744 per share vs. loss of €0.7631 per share (deeper loss per share year on year)
• Pipeline mix (Phase II and Phase III assets, Q2 2026 vs. Q3 2025): 1 product in Phase II and 1 product in Phase III vs. 1 product in Phase II and 1 product in Phase III (stable late stage pipeline for ABIVAX Société Anonyme)

Prefer clean charts over wading through dense earnings tables and footnotes? See ABIVAX Société Anonyme's full visual breakdown, with a clear view of its valuation and how the market is pricing its losses and balance sheet risk, in the company report for ABIVAX Société Anonyme.

Abivax bull case hinges on funding and de risked trials

Optimists argue Abivax is now a fully funded, largely de risked late stage biotech with obefazimod carrying the story. The recent ~€920m equity raise, the royalty certificate buy back and guidance for cash runway into Q4 2029 back up the claim that financing risk is pushed out and that independent commercialization is credible. Positive Phase 3 ABTECT remission data and malignancy rates described as in line with background ulcerative colitis levels support the view that clinical uncertainty around the lead drug has narrowed. The FDA pre NDA meeting in July, which aligned on submission content and timing, is another concrete milestone that fits the bullish script that regulatory review is on a defined track. The widening Q2 loss of €117.433 million, though, underlines that this is still a heavy investment phase, not yet the commercial pay off that the upbeat story implies.

Bear case focuses on losses and execution risk

Skeptics see Abivax as a loss making biotech with large funding needs, complex safety watchpoints and high execution risk around launch. The Q2 net loss of €117.433 million and deeper basic EPS loss of €1.4744 per share give that view real weight, especially when revenue is only €1.201 million. Bears worry that regulatory authorities could ask for more on safety. Updated malignancy data that track with background ulcerative colitis rates and a positive FDA pre NDA interaction weaken that specific fear. Concerns around commercial execution remain intact. Management is hiring commercial, market access and patient services leadership, which shows intent, but also locks in higher operating expense ahead of any obefazimod revenue. The share price retreat of roughly 15% over 30 days indicates that, for now, traders are treating the growing income statement losses as more pressing than the longer term ulcerative colitis and Crohn’s disease opportunity.

Compare that internal story of obefazimod progress, heavier quarterly loss and a retreating share price with what the analyst community is signaling. See the consensus price target analysis for ABIVAX Société Anonyme to check whether current targets line up with the bullish funding narrative or the more cautious focus on widening losses.

Stay Ahead Of The Next Move

With ABIVAX Société Anonyme posting a deep quarterly loss and a sharply weaker share price over the past month, timing matters. Register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how fresh earnings, trial data or regulatory updates shift the risk reward. After you decide to take a position, keep your decisions clear by using the Portfolio Command Center to cut through noise and focus on the most important developments for your holdings. Round out your research by tapping into crowd insight through the Community so you can spot hidden catalysts or early warning signs and stay a step ahead of the market.

Seeking Alternatives Beyond ABIVAX Société Anonyme?

Fresh ideas can gain traction when momentum is building and prices have not yet fully reflected the story. Scan these under the radar for now opportunities before the crowd.

• Spot steady compounders with cleaner balance sheets and calmer trading patterns by running the 230 resilient stocks with low risk scores while these resilient candidates are still flying below most watchlists.
• Look for potential income workhorses while yields remain elevated by scanning the 159 dividend fortresses before prices shift and those payouts draw more attention.
• Track the next wave of infrastructure demand as AI spending affects power and data networks using the 86 AI infrastructure stocks while it still appears early in the cycle.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com